Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
221 hedge funds and large institutions have $3.12B invested in Portola Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 97 increasing their positions, 48 reducing their positions, and 25 closing their positions.
102% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 48
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
12% more capital invested
Capital invested by funds: $2.79B → $3.12B (+$332M)
7% more funds holding
Funds holding: 206 → 221 (+15)
38% less call options, than puts
Call options by funds: $22.9M | Put options by funds: $36.6M
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$137M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$116M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$49.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$32.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$48M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$23.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.8M |
| 4 |
Goldman Sachs
New York
|
-$15M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$11.2M |
PTLA Hedge Fund Activity: Q3 2017 in Review
221 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2017, worth a combined $3.12B — up 12% from $2.79B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PTLA positions and 25 closed out — a net gain of 17 holders — while 97 added to existing stakes and 48 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $137M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $48M sold.
- 221 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2017, up from 206 in Q2 2017.
- Funds reported $3.12B of Portola Pharmaceuticals, Inc. stock for Q3 2017, up 12% quarter-over-quarter.
- 42 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2017 and 25 closed out, a net change of +17 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q3 2017 was PFM Health Sciences, an estimated $137M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q3 2017 was Farallon Capital Management, an estimated $48M sold.
Based on aggregated 13F filings for Q3 2017.